Novel BTK inhibitor reduces multiple sclerosis relapses

Heather Wood
Nature Reviews Neurology · Springer Nature · 2026-11-09 · DOI: 10.1038/s41582-026-01291-y

Аннотация

Nature Reviews Neurology, Published online: 09 November 2026; doi:10.1038/s41582-026-01291-y The novel Bruton’s tyrosine kinase inhibitor remibrutinib is superior to the established disease-modifying drug teriflunomide for reducing relapse rates in people with multiple sclerosis, according to recently released phase III trial data.

Читать у издателя →

Похожие статьи